Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 8/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8213098 | 0.92 | GPR119 (0.52) | CACNA1HGPR119HDAC1HDAC6NAMPT | |
| SCHEMBL8212424 | 0.90 | CACNA1H (0.52) | CACNA1HGPR119USP30HSD11B1OPRD1 | |
| SCHEMBL8210129 | 0.89 | CACNA1H (0.66) | CACNA1HGPR119HDAC1HDAC6NAMPT | |
| SCHEMBL8217950 | 0.87 | CACNA1H (0.54) | CACNA1HGPR119HSD11B1 | |
| SCHEMBL8227878 | 0.87 | CACNA1H (0.54) | CACNA1HGPR119POLBHSD11B1 | |
| SCHEMBL8225731 | 0.87 | CACNA1H (0.48) | CACNA1HGPR119USP30HSD11B1OPRD1 | |
| SCHEMBL8207926 | 0.86 | TRPV1 (0.51) | CACNA1HGPR119HDAC1HDAC6USP30 | |
| SCHEMBL8210549 | 0.85 | CACNA1H (0.65) | CACNA1HGPR119USP30POLB | |
| SCHEMBL8217831 | 0.84 | HDAC1 (0.53) | GPR119HDAC1HDAC6NAMPTGRM5 | |
| SCHEMBL8221320 | 0.83 | GPR119 (0.50) | CACNA1HGPR119HDAC1HDAC6NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-27 | — | — | US | disclosed |
| WO-2008033460-A2 | TREATING PAIN, DIABETES, AND LIPID METABOLISM DISORDERS | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | LIPC, CES1, ZDHHC20 | CACNA1H 2829/4885GPR119 81/4885HDAC1 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.